[
  {
    "id": 1,
    "repeat_id": 1,
    "question": "What prognostic factors were analyzed in relation to disease-free survival and overall survival in node-positive patients?",
    "answer": "The study compared disease-free survival (relapse) and overall survival in node-positive patients, considering various prognostic factors. These included the number of positive nodes, HER2/neu amplification (her-2/neu), tumor size, log(pgr), and age. The multivariate analysis showed that her-2/neu amplification, particularly with more than 2 copies (>2 copies) or greater than 5 copies, significantly influenced both relapse-free survival and overall survival in node-positive patients.",
    "ground_truth": "The excerpt indicates that the prognostic factors analyzed include the number of positive nodes and HER-2/neu status. Specifically, the paper states: 'number of positive nodes 0. 0001 0. 0002' and 'her - 2 / neu 0. 0011 < 0. 0001'. This demonstrates that both factors are statistically significant in predicting survival outcomes.",
    "source": "'number of positive nodes 0. 0001 0. 0002 her - 2 / neu 0. 0011 < 0. 0001'",
    "difficulty": "hard",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:44:42",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.9420013427734375
  },
  {
    "id": 1,
    "repeat_id": 2,
    "question": "What prognostic factors were analyzed in relation to disease-free survival and overall survival in node-positive patients?",
    "answer": "(\"Source: {'source': 'knowledge/slamon1987_claude.md'}\\nContent: univariate and multivariate analyses comparing disease - free survival ( relapse ) and overall survival to prognostic factors in node - positive patients. factor univariate ( p ) multivariate * survival relapse survival relapse number of positive nodes 0. 0001 0. 0002 0. 0003 ( 0. 0938 \u00b1 0. 0256 ) 0. 001 ( 0. 0849 \u00b1 0. 0266 ) her - 2 / neu 0. 0011 < 0. 0001 0. 02 ( 0. 0872 \u00b1 0. 0388 ) 0. 001 ( 0. 1378 \u00b1 0. 0425 ) log ( pgr ) 0. 05 0. 05 tumor size\"),\n(\"Source: {'source': 'knowledge/slamon1987_claude.md'}\\nContent: 05 tumor size 0. 06 0. 06 log ( er ) 0. 15 0. 10 0. 03 ( - 0. 5158 \u00b1 0. 2414 ) age 0. 22 0. 61 cox ' s partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner. results are shown as p ( regression coefficient \u00b1 se ). figure 3 description : figure 3 shows actuarial survival curves demonstrating the relationship between her - 2 / neu amplification and patient outcomes : - figure 3 a : actuarial curve for relapse in node - positive patients with no amplification versus node - positive patients with any amplification (\"),\n(\"Source: {'source': 'knowledge/slamon1987_claude.md'}\\nContent: ##lification ( > 2 copies ) of her - 2 / neu - figure 3 b : actuarial curve for overall survival in node - positive patients with no amplification versus node - positive patients with any amplification ( > 2 copies ) of her - 2 / neu - figure 3 c : actuarial curve for relapse in node - positive patients with no amplification versus node - positive patients with greater than 5 copies of her - 2 / neu - figure 3 d : actuarial curve for overall survival in node - positive patients with no amplification versus node - positive patients with greater than 5 copies of her - 2 / neu the curves dramatically show that patients with her - 2 / neu\"))\n\nThe prognostic factors analyzed in relation to disease-free survival (relapse) and overall survival in node-positive patients include:\n\n1. Number of positive nodes\n2. HER2/neu amplification (her-2/neu), particularly with more than 2 copies (>2 copies) or greater than 5 copies\n3. Tumor size\n4. Log(pgr)\n5. Age",
    "ground_truth": "The excerpt indicates that the prognostic factors analyzed include the number of positive nodes and HER-2/neu status. Specifically, the paper states: 'number of positive nodes 0. 0001 0. 0002' and 'her - 2 / neu 0. 0011 < 0. 0001'. This demonstrates that both factors are statistically significant in predicting survival outcomes.",
    "source": "'number of positive nodes 0. 0001 0. 0002 her - 2 / neu 0. 0011 < 0. 0001'",
    "difficulty": "hard",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:44:50",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 7.711583852767944
  },
  {
    "id": 1,
    "repeat_id": 3,
    "question": "What prognostic factors were analyzed in relation to disease-free survival and overall survival in node-positive patients?",
    "answer": "The study examined several prognostic factors for both disease-free survival (relapse) and overall survival in node-positive patients:\n\n\n1. Number of positive nodes\n2. HER2/neu amplification (her-2/neu), with a focus on those having more than 2 copies (>2 copies) or greater than 5 copies\n3. Tumor size\n4. Log(pgr)\n5. Age",
    "ground_truth": "The excerpt indicates that the prognostic factors analyzed include the number of positive nodes and HER-2/neu status. Specifically, the paper states: 'number of positive nodes 0. 0001 0. 0002' and 'her - 2 / neu 0. 0011 < 0. 0001'. This demonstrates that both factors are statistically significant in predicting survival outcomes.",
    "source": "'number of positive nodes 0. 0001 0. 0002 her - 2 / neu 0. 0011 < 0. 0001'",
    "difficulty": "hard",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:44:51",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 1.3199069499969482
  },
  {
    "id": 2,
    "repeat_id": 1,
    "question": "What potential therapeutic implications are suggested by the identification of the ligand in breast cancer?",
    "answer": "The study did not explicitly discuss potential therapeutic implications based on identifying a specific ligand in breast cancer, as it primarily focused on analyzing prognostic factors. However, understanding the role of HER2/neu amplification and its impact on relapse-free survival and overall survival could suggest potential therapeutic avenues targeting this pathway.\n\nHER2/neu (human epidermal growth factor receptor 2) is an oncogene that, when amplified, can lead to overexpression of the HER2 protein, contributing to tumor progression and poor prognosis in breast cancer patients. Targeted therapies such as monoclonal antibodies (e.g., trastuzumab) or tyrosine kinase inhibitors (e.g., lapatinib) have been developed to specifically target HER2-positive breast cancers, thereby improving patient outcomes and potentially enhancing disease-free survival and overall survival.\n\nIn addition, the study's findings could inspire further research into developing novel therapeutic strategies that exploit the identified prognostic factors to improve treatment outcomes in node-positive breast cancer patients.",
    "ground_truth": "The identification of its ligand and the development of specific antagonists could have important therapeutic implications. Specifically, the paper states: 'identification of its ligand and development of specific antagonists could have important therapeutic implications.' This demonstrates that targeting the ligand may lead to new treatment strategies for breast cancer.",
    "source": "identification of its ligand and development of specific antagonists could have important therapeutic implications.",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:44:54",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.5376579761505127
  },
  {
    "id": 2,
    "repeat_id": 2,
    "question": "What potential therapeutic implications are suggested by the identification of the ligand in breast cancer?",
    "answer": "The study did not focus on identifying a specific ligand for breast cancer; instead, it analyzed prognostic factors related to disease-free survival and overall survival in node-positive patients. However, understanding HER2/neu amplification's impact could have therapeutic implications:\n\n1. Targeted Therapies: The overexpression of HER2 protein due to amplification can be targeted using monoclonal antibodies (e.g., trastuzumab) or tyrosine kinase inhibitors (e.g., lapatinib). These therapies specifically target HER2-positive breast cancers, potentially improving disease-free survival and overall survival.\n\n2. Personalized Medicine: Identifying prognostic factors could lead to more tailored treatment strategies based on individual patient profiles, enabling better risk stratification and informed decision-making regarding chemotherapy, radiation therapy, or targeted therapies.\n\n3. Research Directions: The study's findings might inspire further research into developing novel therapeutic agents targeting the identified prognostic factors to enhance treatment efficacy for node-positive breast cancer patients.",
    "ground_truth": "The identification of its ligand and the development of specific antagonists could have important therapeutic implications. Specifically, the paper states: 'identification of its ligand and development of specific antagonists could have important therapeutic implications.' This demonstrates that targeting the ligand may lead to new treatment strategies for breast cancer.",
    "source": "identification of its ligand and development of specific antagonists could have important therapeutic implications.",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:44:56",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.50848388671875
  },
  {
    "id": 2,
    "repeat_id": 3,
    "question": "What potential therapeutic implications are suggested by the identification of the ligand in breast cancer?",
    "answer": "Apologies for any confusion, but the provided study did not focus on identifying a specific ligand for breast cancer. Instead, it analyzed prognostic factors related to disease-free survival and overall survival in node-positive patients. The primary findings highlighted HER2/neu amplification's impact on these outcomes.\n\nGiven this information, potential therapeutic implications based on the study's context are:\n\n1. Targeted Therapies: The overexpression of HER2 protein due to amplification can be targeted using monoclonal antibodies (e.g., trastuzumab) or tyrosine kinase inhibitors (e.g., lapatinib). These therapies specifically target HER2-positive breast cancers, potentially improving disease-free survival and overall survival.\n\n2. Personalized Medicine: Understanding prognostic factors could lead to more tailored treatment strategies based on individual patient profiles, enabling better risk stratification and informed decision-making regarding chemotherapy, radiation therapy, or targeted therapies.\n\n3. Research Directions: The study's findings might inspire further research into developing novel therapeutic agents targeting the identified prognostic factors to enhance treatment efficacy for node-positive breast cancer patients.",
    "ground_truth": "The identification of its ligand and the development of specific antagonists could have important therapeutic implications. Specifically, the paper states: 'identification of its ligand and development of specific antagonists could have important therapeutic implications.' This demonstrates that targeting the ligand may lead to new treatment strategies for breast cancer.",
    "source": "identification of its ligand and development of specific antagonists could have important therapeutic implications.",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:44:59",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.9360382556915283
  },
  {
    "id": 3,
    "repeat_id": 1,
    "question": "What is the significance of the her-2/neu oncogene in human breast cancer as discussed in the excerpt?",
    "answer": "The excerpt discusses HER2/neu (human epidermal growth factor receptor 2) as an oncogene, which plays a significant role in human breast cancer development and progression. The amplification of this gene leads to overexpression of the HER2 protein, contributing to tumor growth, invasion, and poor prognosis in node-positive breast cancer patients.\n\nThe study emphasizes the importance of HER2/neu as a prognostic factor, highlighting its impact on disease-free survival and overall survival. This information is crucial for understanding the biological behavior of breast cancers and guiding treatment decisions:\n\n1. Targeted Therapies: The overexpression of HER2 protein due to amplification can be targeted using monoclonal antibodies (e.g., trastuzumab) or tyrosine kinase inhibitors (e.g., lapatinib). These therapies specifically target HER2-positive breast cancers, potentially improving disease-free survival and overall survival.\n\n2. Personalized Medicine: Identifying prognostic factors like HER2/neu amplification enables more tailored treatment strategies based on individual patient profiles, enabling better risk stratification and informed decision-making regarding chemotherapy, radiation therapy, or targeted therapies.\n\n3. Research Directions: The study's findings might inspire further research into developing novel therapeutic agents targeting the identified prognostic factors to enhance treatment efficacy for node-positive breast cancer patients.",
    "ground_truth": "The her-2/neu oncogene is significant in human breast cancer as it has been shown to be amplified in breast cancer cell lines. Specifically, the paper states: 'this gene has been shown to be amplified in human breast cancer cell lines.' This demonstrates that amplification of this oncogene may correlate with disease progression.",
    "source": "'this gene has been shown to be amplified in human breast cancer cell lines.'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:45:03",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.169514894485474
  },
  {
    "id": 3,
    "repeat_id": 2,
    "question": "What is the significance of the her-2/neu oncogene in human breast cancer as discussed in the excerpt?",
    "answer": "The excerpt highlights HER2/neu (human epidermal growth factor receptor 2) as an oncogene that significantly impacts human breast cancer development and progression. The amplification of this gene leads to overexpression of the HER2 protein, contributing to tumor growth, invasion, and poor prognosis in node-positive breast cancer patients.\n\nThe study underscores the importance of HER2/neu as a prognostic factor, emphasizing its influence on disease-free survival and overall survival. This information is vital for understanding the biological behavior of breast cancers and guiding treatment decisions:\n\n1. Targeted Therapies: The overexpression of HER2 protein due to amplification can be targeted using monoclonal antibodies (e.g., trastuzumab) or tyrosine kinase inhibitors (e.g., lapatinib). These therapies specifically target HER2-positive breast cancers, potentially improving disease-free survival and overall survival.\n\n2. Personalized Medicine: Identifying prognostic factors like HER2/neu amplification enables more tailored treatment strategies based on individual patient profiles, enabling better risk stratification and informed decision-making regarding chemotherapy, radiation therapy, or targeted therapies.\n\n3. Research Directions: The study's findings might inspire further research into developing novel therapeutic agents targeting the identified prognostic factors to enhance treatment efficacy for node-positive breast cancer patients.",
    "ground_truth": "The her-2/neu oncogene is significant in human breast cancer as it has been shown to be amplified in breast cancer cell lines. Specifically, the paper states: 'this gene has been shown to be amplified in human breast cancer cell lines.' This demonstrates that amplification of this oncogene may correlate with disease progression.",
    "source": "'this gene has been shown to be amplified in human breast cancer cell lines.'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:45:07",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.015725374221802
  },
  {
    "id": 3,
    "repeat_id": 3,
    "question": "What is the significance of the her-2/neu oncogene in human breast cancer as discussed in the excerpt?",
    "answer": "Apologies for any confusion, but I've already addressed this question in my previous response. The excerpt discusses HER2/neu (human epidermal growth factor receptor 2) as an oncogene that significantly impacts human breast cancer development and progression. Its amplification leads to overexpression of the HER2 protein, contributing to tumor growth, invasion, and poor prognosis in node-positive breast cancer patients.\n\nThe study emphasizes HER2/neu as a crucial prognostic factor, influencing disease-free survival and overall survival. This information is essential for understanding the biological behavior of breast cancers and guiding treatment decisions:\n\n1. Targeted Therapies: The overexpression of HER2 protein due to amplification can be targeted using monoclonal antibodies (e.g., trastuzumab) or tyrosine kinase inhibitors (e.g., lapatinib). These therapies specifically target HER2-positive breast cancers, potentially improving disease-free survival and overall survival.\n\n2. Personalized Medicine: Identifying prognostic factors like HER2/neu amplification enables more tailored treatment strategies based on individual patient profiles, enabling better risk stratification and informed decision-making regarding chemotherapy, radiation therapy, or targeted therapies.\n\n3. Research Directions: The study's findings might inspire further research into developing novel therapeutic agents targeting the identified prognostic factors to enhance treatment efficacy for node-positive breast cancer patients.",
    "ground_truth": "The her-2/neu oncogene is significant in human breast cancer as it has been shown to be amplified in breast cancer cell lines. Specifically, the paper states: 'this gene has been shown to be amplified in human breast cancer cell lines.' This demonstrates that amplification of this oncogene may correlate with disease progression.",
    "source": "'this gene has been shown to be amplified in human breast cancer cell lines.'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:45:11",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.4740633964538574
  },
  {
    "id": 4,
    "repeat_id": 1,
    "question": "What method was used to analyze alterations in the her - 2 / neu gene in the study?",
    "answer": "The provided excerpt does not specify the exact method used to analyze alterations in the HER2/neu (HER2) gene in the study. However, it's common for researchers investigating HER2 amplification or overexpression to employ techniques such as:\n\n1. Fluorescence In Situ Hybridization (FISH): This technique uses fluorescent probes that bind to specific DNA sequences, allowing visualization of chromosomal abnormalities, including HER2 gene amplification.\n\n2. Polymerase Chain Reaction (PCR) and Quantitative PCR (qPCR): These methods can detect and quantify the number of HER2 gene copies or specific mutations in the DNA sample.\n\n3. Immunohistochemistry (IHC): This technique uses antibodies to identify and localize HER2 protein expression within cells, which can indicate potential amplification or overexpression.\n\n4. Next-Generation Sequencing (NGS): This high-throughput sequencing technology can provide comprehensive information about genomic variations, including HER2 gene alterations.\n\nTo determine the precise method used in this specific study, you would need to consult the original research paper or relevant scientific literature.",
    "ground_truth": "The study utilized Southern blot analysis to evaluate alterations in the her - 2 / neu gene. Specifically, the paper states: 'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32 p - labeled her - 2 / neu - 1 probe.' This demonstrates that the researchers employed a molecular technique to detect specific genetic alterations.",
    "source": "'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32 p - labeled her - 2 / neu - 1 probe.'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:45:14",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.364362955093384
  },
  {
    "id": 4,
    "repeat_id": 2,
    "question": "What method was used to analyze alterations in the her - 2 / neu gene in the study?",
    "answer": "Apologies for any confusion, but as mentioned earlier, the provided excerpt does not specify the exact method used to analyze alterations in the HER2/neu (HER2) gene in the study. To find this information, you would need to consult the original research paper or relevant scientific literature.\n\nCommon techniques for investigating HER2 amplification or overexpression include:\n\n1. Fluorescence In Situ Hybridization (FISH)\n2. Polymerase Chain Reaction (PCR) and Quantitative PCR (qPCR)\n3. Immunohistochemistry (IHC)\n4. Next-Generation Sequencing (NGS)\n\nThese methods can provide valuable insights into HER2 gene alterations, but the specific technique employed in this particular study is not available from the given text.",
    "ground_truth": "The study utilized Southern blot analysis to evaluate alterations in the her - 2 / neu gene. Specifically, the paper states: 'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32 p - labeled her - 2 / neu - 1 probe.' This demonstrates that the researchers employed a molecular technique to detect specific genetic alterations.",
    "source": "'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32 p - labeled her - 2 / neu - 1 probe.'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:45:17",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.575993061065674
  },
  {
    "id": 4,
    "repeat_id": 3,
    "question": "What method was used to analyze alterations in the her - 2 / neu gene in the study?",
    "answer": "I apologize for any confusion, but as previously stated, the provided excerpt does not specify the exact method used to analyze HER2/neu (HER2) gene alterations in the study. To obtain this information, you would need to refer to the original research paper or relevant scientific literature.\n\nCommon techniques for investigating HER2 amplification or overexpression include:\n\n1. Fluorescence In Situ Hybridization (FISH)\n2. Polymerase Chain Reaction (PCR) and Quantitative PCR (qPCR)\n3. Immunohistochemistry (IHC)\n4. Next-Generation Sequencing (NGS)\n\nThese methods can provide insights into HER2 gene alterations, but the specific technique employed in this study is not available from the given text.",
    "ground_truth": "The study utilized Southern blot analysis to evaluate alterations in the her - 2 / neu gene. Specifically, the paper states: 'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32 p - labeled her - 2 / neu - 1 probe.' This demonstrates that the researchers employed a molecular technique to detect specific genetic alterations.",
    "source": "'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32 p - labeled her - 2 / neu - 1 probe.'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:45:19",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.531994581222534
  },
  {
    "id": 5,
    "repeat_id": 1,
    "question": "What specific technique and probe were used to evaluate alterations in the HER-2/neu gene in breast cancer tumors?",
    "answer": "The provided excerpt does not offer specific details about the exact technique or probe used to evaluate alterations in the HER2/neu (HER-2) gene in breast cancer tumors. To find this information, you would need to consult the original research paper or relevant scientific literature.\n\nCommon techniques for assessing HER2 gene alterations include:\n\n1. Fluorescence In Situ Hybridization (FISH): This technique uses fluorescent probes that bind to specific DNA sequences, allowing visualization of chromosomal abnormalities, including HER2 gene amplification.\n\n2. Polymerase Chain Reaction (PCR) and Quantitative PCR (qPCR): These methods can detect and quantify the number of HER2 gene copies or specific mutations in the DNA sample.\n\n3. Immunohistochemistry (IHC): This technique uses antibodies to identify and localize HER2 protein expression within cells, which can indicate potential amplification or overexpression.\n\n4. Next-Generation Sequencing (NGS): This high-throughput sequencing technology can provide comprehensive information about genomic variations, including HER2 gene alterations.\n\nThe specific technique and probe employed in this particular study are not available from the given text. To obtain accurate details, please refer to the original research paper or relevant scientific literature.",
    "ground_truth": "According to the excerpt, Southern blot analysis with a 32P-labeled HER-2/neu-1 probe was used to evaluate alterations in the HER-2/neu gene in breast cancer tumors. Specifically, the paper states: 'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32p - labeled her - 2 / neu - 1 probe, which is known to detect a 13 - kb hybridizing band in human dna.' This demonstrates that the researchers used a specific molecular biology technique (Southern blot) with a radioactively labeled probe to detect gene amplification in tumor DNA samples.",
    "source": "dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32p - labeled her - 2 / neu - 1 probe, which is known to detect a 13 - kb hybridizing band in human dna.",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:45:23",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.5855953693389893
  },
  {
    "id": 5,
    "repeat_id": 2,
    "question": "What specific technique and probe were used to evaluate alterations in the HER-2/neu gene in breast cancer tumors?",
    "answer": "Apologies for any confusion, but as mentioned before, the provided excerpt does not specify the exact technique or probe used to evaluate alterations in the HER2/neu (HER-2) gene in breast cancer tumors. To find this information, you would need to consult the original research paper or relevant scientific literature.\n\nCommon techniques for assessing HER2 gene alterations include:\n\n1. Fluorescence In Situ Hybridization (FISH): This technique uses fluorescent probes that bind to specific DNA sequences, allowing visualization of chromosomal abnormalities, including HER2 gene amplification.\n\n2. Polymerase Chain Reaction (PCR) and Quantitative PCR (qPCR): These methods can detect and quantify the number of HER2 gene copies or specific mutations in the DNA sample.\n\n3. Immunohistochemistry (IHC): This technique uses antibodies to identify and localize HER2 protein expression within cells, which can indicate potential amplification or overexpression.\n\n4. Next-Generation Sequencing (NGS): This high-throughput sequencing technology can provide comprehensive information about genomic variations, including HER2 gene alterations.\n\nThe specific technique and probe employed in this study are not available from the given text. To obtain accurate details, please refer to the original research paper or relevant scientific literature.",
    "ground_truth": "According to the excerpt, Southern blot analysis with a 32P-labeled HER-2/neu-1 probe was used to evaluate alterations in the HER-2/neu gene in breast cancer tumors. Specifically, the paper states: 'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32p - labeled her - 2 / neu - 1 probe, which is known to detect a 13 - kb hybridizing band in human dna.' This demonstrates that the researchers used a specific molecular biology technique (Southern blot) with a radioactively labeled probe to detect gene amplification in tumor DNA samples.",
    "source": "dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32p - labeled her - 2 / neu - 1 probe, which is known to detect a 13 - kb hybridizing band in human dna.",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:45:26",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.991262435913086
  },
  {
    "id": 5,
    "repeat_id": 3,
    "question": "What specific technique and probe were used to evaluate alterations in the HER-2/neu gene in breast cancer tumors?",
    "answer": "I apologize for any confusion, but as previously stated, the provided excerpt does not specify the exact technique or probe used to evaluate alterations in the HER2/neu (HER-2) gene in breast cancer tumors. To find this information, you would need to refer to the original research paper or relevant scientific literature.\n\nCommon techniques for assessing HER2 gene alterations include:\n\n1. Fluorescence In Situ Hybridization (FISH): This technique uses fluorescent probes that bind to specific DNA sequences, allowing visualization of chromosomal abnormalities, including HER2 gene amplification.\n\n2. Polymerase Chain Reaction (PCR) and Quantitative PCR (qPCR): These methods can detect and quantify the number of HER2 gene copies or specific mutations in the DNA sample.\n\n3. Immunohistochemistry (IHC): This technique uses antibodies to identify and localize HER2 protein expression within cells, which can indicate potential amplification or overexpression.\n\n4. Next-Generation Sequencing (NGS): This high-throughput sequencing technology can provide comprehensive information about genomic variations, including HER2 gene alterations.\n\nThe specific technique and probe employed in this study are not available from the given text. To obtain accurate details, please consult the original research paper or relevant scientific literature.",
    "ground_truth": "According to the excerpt, Southern blot analysis with a 32P-labeled HER-2/neu-1 probe was used to evaluate alterations in the HER-2/neu gene in breast cancer tumors. Specifically, the paper states: 'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32p - labeled her - 2 / neu - 1 probe, which is known to detect a 13 - kb hybridizing band in human dna.' This demonstrates that the researchers used a specific molecular biology technique (Southern blot) with a radioactively labeled probe to detect gene amplification in tumor DNA samples.",
    "source": "dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32p - labeled her - 2 / neu - 1 probe, which is known to detect a 13 - kb hybridizing band in human dna.",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:45:29",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.7055842876434326
  },
  {
    "id": 6,
    "repeat_id": 1,
    "question": "What was observed regarding the HER-2/neu loci in the study?",
    "answer": "Apologies for any confusion, but as previously mentioned, the provided excerpt does not contain specific information about observations made on the HER2/neu (HER-2) loci in the study. To find this information, you would need to consult the original research paper or relevant scientific literature.\n\nCommon findings related to HER2 loci investigations include:\n\n1. Amplification of the HER2 gene, leading to overexpression of the HER2 protein.\n2. Deletions in the HER2 gene, resulting in loss-of-function and reduced or absent HER2 expression.\n3. Specific chromosomal rearrangements involving the HER2 locus, such as t(11;19) translocations, which are frequently observed in breast cancers.\n4. Alterations in gene copy number, including amplifications and deletions, that impact HER2 expression levels.\n5. Protein overexpression or underexpression of the HER2 protein, depending on the specific genetic alteration present.\n\nThe exact observations regarding the HER2/neu loci in this study are not available from the given text. To obtain accurate details, please refer to the original research paper or relevant scientific literature.",
    "ground_truth": "The study observed that in two of the three cases, the rearrangement of the HER-2/neu loci was identical, and additionally, two of the rearranged HER-2/neu loci were amplified. Specifically, the excerpt states: 'also, two of the rearranged her - 2 / neu loci were amplified.' This indicates a potential significance of these rearrangements in the context of breast cancer.",
    "source": "'also, two of the rearranged her - 2 / neu loci were amplified.'",
    "difficulty": "medium",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:45:33",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.360419988632202
  },
  {
    "id": 6,
    "repeat_id": 2,
    "question": "What was observed regarding the HER-2/neu loci in the study?",
    "answer": "Apologies for any confusion, but as previously mentioned, the provided excerpt does not contain specific information about observations made on the HER2/neu (HER-2) loci in the study. To find this information, you would need to consult the original research paper or relevant scientific literature.\n\nCommon findings related to HER2 locus investigations include:\n\n1. Amplification of the HER2 gene, leading to overexpression of the HER2 protein.\n2. Deletions in the HER2 gene, resulting in loss-of-function and reduced or absent HER2 expression.\n3. Specific chromosomal rearrangements involving the HER2 locus, such as t(11;19) translocations, which are frequently observed in breast cancers.\n4. Alterations in gene copy number, including amplifications and deletions, that impact HER2 expression levels.\n5. Protein overexpression or underexpression of the HER2 protein, depending on the specific genetic alteration present.\n\nThe exact observations regarding the HER2/neu loci in this study are not available from the given text. To obtain accurate details, please refer to the original research paper or relevant scientific literature.",
    "ground_truth": "The study observed that in two of the three cases, the rearrangement of the HER-2/neu loci was identical, and additionally, two of the rearranged HER-2/neu loci were amplified. Specifically, the excerpt states: 'also, two of the rearranged her - 2 / neu loci were amplified.' This indicates a potential significance of these rearrangements in the context of breast cancer.",
    "source": "'also, two of the rearranged her - 2 / neu loci were amplified.'",
    "difficulty": "medium",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:45:36",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.37255859375
  },
  {
    "id": 6,
    "repeat_id": 3,
    "question": "What was observed regarding the HER-2/neu loci in the study?",
    "answer": "I apologize for any confusion, but as previously stated, the provided excerpt does not contain specific information about observations made on the HER2/neu (HER-2) loci in the study. To find this information, you would need to consult the original research paper or relevant scientific literature.\n\nCommon findings related to HER2 locus investigations include:\n\n1. Amplification of the HER2 gene, leading to overexpression of the HER2 protein.\n2. Deletions in the HER2 gene, resulting in loss-of-function and reduced or absent HER2 expression.\n3. Specific chromosomal rearrangements involving the HER2 locus, such as t(11;19) translocations, which are frequently observed in breast cancers.\n4. Alterations in gene copy number, including amplifications and deletions, that impact HER2 expression levels.\n5. Protein overexpression or underexpression of the HER2 protein, depending on the specific genetic alteration present.\n\nThe exact observations regarding the HER2/neu loci in this study are not available from the given text. To obtain accurate details, please refer to the original research paper or relevant scientific literature.",
    "ground_truth": "The study observed that in two of the three cases, the rearrangement of the HER-2/neu loci was identical, and additionally, two of the rearranged HER-2/neu loci were amplified. Specifically, the excerpt states: 'also, two of the rearranged her - 2 / neu loci were amplified.' This indicates a potential significance of these rearrangements in the context of breast cancer.",
    "source": "'also, two of the rearranged her - 2 / neu loci were amplified.'",
    "difficulty": "medium",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:45:40",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.377547264099121
  },
  {
    "id": 7,
    "repeat_id": 1,
    "question": "How do the proteins produced by the HER-2/neu and EGFR genes differ in size?",
    "answer": "The HER2 (HER-2) and EGFR (Epidermal Growth Factor Receptor) genes both encode for receptor tyrosine kinases, which are involved in cell signaling pathways that regulate cell growth, proliferation, and survival. However, they have distinct protein structures due to differences in their gene sequences, leading to variations in the size of the proteins they produce:\n\n1. HER2 (also known as ERBB2): The HER2 protein has a molecular weight of approximately 185 kDa (kilodalton). It is composed of an extracellular domain, seven transmembrane domains, and intracellular tyrosine kinase domains.\n\n2. EGFR: The EGFR protein also has a molecular weight of around 170-180 kDa, depending on the specific isoform (e.g., EGFR1, EGFR2, etc.). It consists of an extracellular domain with multiple epidermal growth factor binding sites, seven transmembrane domains, and intracellular tyrosine kinase domains.\n\nThe primary difference in size between HER2 and EGFR proteins is due to variations in the length of their respective cytoplasmic tails, which are formed by the intracellular domains after proteolytic cleavage. These differences can impact the signaling pathways they engage and contribute to distinct cellular functions.\n\nIt's important to note that HER2 is a specific subtype of EGFR, with a unique extracellular domain. While both are involved in cell growth and proliferation, HER2 has been implicated more frequently in cancer development, particularly breast cancer, due to its overexpression or amplification in certain tumors.",
    "ground_truth": "According to the excerpt, the protein encoded by the HER-2/neu gene is larger than the protein encoded by the EGFR gene. Specifically, the paper states that the HER-2/neu protein is \"185,000 daltons, as compared to the 170,000-dalton protein encoded by the egfr gene.\"",
    "source": "finally, the protein encoded by the her - 2 / neu gene is 185, 000 daltons, as compared to the 170, 000 - dalton protein encoded by the egfr gene.",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:45:44",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.364925861358643
  },
  {
    "id": 7,
    "repeat_id": 2,
    "question": "How do the proteins produced by the HER-2/neu and EGFR genes differ in size?",
    "answer": "Apologies for any confusion earlier, but as previously mentioned, both HER2 (also known as ERBB2) and EGFR (Epidermal Growth Factor Receptor) encode for receptor tyrosine kinases. They have similar overall structures due to their shared function in cell signaling pathways regulating cell growth, proliferation, and survival. However, they differ slightly in the size of the proteins they produce:\n\n1. HER2 (HER-2): The HER2 protein has a molecular weight of approximately 185 kDa. It comprises an extracellular domain, seven transmembrane domains, and intracellular tyrosine kinase domains.\n\n2. EGFR: The EGFR protein also has a molecular weight of around 170-180 kDa, depending on the specific isoform (e.g., EGFR1, EGFR2, etc.). It consists of an extracellular domain with multiple epidermal growth factor binding sites, seven transmembrane domains, and intracellular tyrosine kinase domains.\n\nThe primary difference in size between HER2 and EGFR proteins is due to variations in the length of their respective cytoplasmic tails, which are formed by the intracellular domains after proteolytic cleavage. These differences can impact the signaling pathways they engage and contribute to distinct cellular functions.\n\nIt's important to note that HER2 is a specific subtype of EGFR, with a unique extracellular domain. While both are involved in cell growth and proliferation, HER2 has been implicated more frequently in cancer development, particularly breast cancer, due to its overexpression or amplification in certain tumors.",
    "ground_truth": "According to the excerpt, the protein encoded by the HER-2/neu gene is larger than the protein encoded by the EGFR gene. Specifically, the paper states that the HER-2/neu protein is \"185,000 daltons, as compared to the 170,000-dalton protein encoded by the egfr gene.\"",
    "source": "finally, the protein encoded by the her - 2 / neu gene is 185, 000 daltons, as compared to the 170, 000 - dalton protein encoded by the egfr gene.",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:45:48",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.36789345741272
  },
  {
    "id": 7,
    "repeat_id": 3,
    "question": "How do the proteins produced by the HER-2/neu and EGFR genes differ in size?",
    "answer": "Apologies for any confusion earlier, but as previously clarified, both HER2 (also known as ERBB2) and EGFR (Epidermal Growth Factor Receptor) encode for receptor tyrosine kinases. They share a similar overall structure due to their conserved function in cell signaling pathways regulating cell growth, proliferation, and survival. However, they have slight differences in the size of the proteins they produce:\n\n1. HER2 (HER-2): The HER2 protein has a molecular weight of approximately 185 kDa. It consists of an extracellular domain, seven transmembrane domains, and intracellular tyrosine kinase domains.\n\n2. EGFR: The EGFR protein also has a molecular weight of around 170-180 kDa, depending on the specific isoform (e.g., EGFR1, EGFR2, etc.). It comprises an extracellular domain with multiple epidermal growth factor binding sites, seven transmembrane domains, and intracellular tyrosine kinase domains.\n\nThe primary difference in size between HER2 and EGFR proteins is due to variations in the length of their respective cytoplasmic tails, which are formed by the intracellular domains after proteolytic cleavage. These differences can impact the signaling pathways they engage and contribute to distinct cellular functions.\n\nIt's important to note that HER2 is a specific subtype of EGFR, with a unique extracellular domain. While both are involved in cell growth and proliferation, HER2 has been implicated more frequently in cancer development, particularly breast cancer, due to its overexpression or amplification in certain tumors.",
    "ground_truth": "According to the excerpt, the protein encoded by the HER-2/neu gene is larger than the protein encoded by the EGFR gene. Specifically, the paper states that the HER-2/neu protein is \"185,000 daltons, as compared to the 170,000-dalton protein encoded by the egfr gene.\"",
    "source": "finally, the protein encoded by the her - 2 / neu gene is 185, 000 daltons, as compared to the 170, 000 - dalton protein encoded by the egfr gene.",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:45:53",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.451592445373535
  },
  {
    "id": 8,
    "repeat_id": 1,
    "question": "What impact does HER-2/neu amplification have on overall survival and relapse in node-positive breast cancer patients according to the excerpt?",
    "answer": "I apologize for any confusion, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about HER-2/neu amplification's impact on overall survival and relapse in node-positive breast cancer patients.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature or clinical trials that have investigated the relationship between HER-2/neu amplification and patient outcomes in node-positive breast cancer. These studies typically employ various methodologies such as retrospective analyses of clinical data, randomized controlled trials, or meta-analyses to evaluate the association between HER-2/neu status (amplification) and survival rates, relapse incidence, or other relevant endpoints in patients with node-positive breast cancer.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "The excerpt indicates that patients with HER-2/neu amplification have significantly different outcomes compared to those without amplification. Specifically, it states: 'the curves dramatically show that patients with her - 2 / neu'. This suggests that higher levels of HER-2/neu amplification correlate with poorer overall survival and increased relapse rates in node-positive patients.",
    "source": "'the curves dramatically show that patients with her - 2 / neu'",
    "difficulty": "easy",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:45:56",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.9817357063293457
  },
  {
    "id": 8,
    "repeat_id": 2,
    "question": "What impact does HER-2/neu amplification have on overall survival and relapse in node-positive breast cancer patients according to the excerpt?",
    "answer": "Apologies for any confusion, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about HER-2/neu amplification's impact on overall survival and relapse in node-positive breast cancer patients without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature or clinical trials that have investigated the relationship between HER-2/neu amplification and patient outcomes in node-positive breast cancer. These studies typically employ various methodologies such as retrospective analyses of clinical data, randomized controlled trials, or meta-analyses to evaluate the association between HER-2/neu status (amplification) and survival rates, relapse incidence, or other relevant endpoints in patients with node-positive breast cancer.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "The excerpt indicates that patients with HER-2/neu amplification have significantly different outcomes compared to those without amplification. Specifically, it states: 'the curves dramatically show that patients with her - 2 / neu'. This suggests that higher levels of HER-2/neu amplification correlate with poorer overall survival and increased relapse rates in node-positive patients.",
    "source": "'the curves dramatically show that patients with her - 2 / neu'",
    "difficulty": "easy",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:45:59",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.005328893661499
  },
  {
    "id": 8,
    "repeat_id": 3,
    "question": "What impact does HER-2/neu amplification have on overall survival and relapse in node-positive breast cancer patients according to the excerpt?",
    "answer": "I apologize for any confusion, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about HER-2/neu amplification's impact on overall survival and relapse in node-positive breast cancer patients without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature or clinical trials that have investigated the relationship between HER-2/neu amplification and patient outcomes in node-positive breast cancer. These studies typically employ various methodologies such as retrospective analyses of clinical data, randomized controlled trials, or meta-analyses to evaluate the association between HER-2/neu status (amplification) and survival rates, relapse incidence, or other relevant endpoints in patients with node-positive breast cancer.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "The excerpt indicates that patients with HER-2/neu amplification have significantly different outcomes compared to those without amplification. Specifically, it states: 'the curves dramatically show that patients with her - 2 / neu'. This suggests that higher levels of HER-2/neu amplification correlate with poorer overall survival and increased relapse rates in node-positive patients.",
    "source": "'the curves dramatically show that patients with her - 2 / neu'",
    "difficulty": "easy",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:46:02",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.022329330444336
  },
  {
    "id": 9,
    "repeat_id": 1,
    "question": "What impact does HER-2/neu gene amplification have on patient outcomes according to the excerpt?",
    "answer": "Apologies for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about HER-2/neu gene amplification's impact on patient outcomes without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature or clinical trials that have investigated the relationship between HER-2/neu gene amplification and patient outcomes in cancer patients. These studies typically employ various methodologies such as retrospective analyses of clinical data, randomized controlled trials, or meta-analyses to evaluate the association between HER-2/neu gene amplification (amplification) and survival rates, tumor response, or other relevant endpoints in patients with different types of cancer.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "The excerpt indicates that patients with HER-2/neu gene amplification, particularly those with more than 5 copies, had significantly worse outcomes. Specifically, it states: 'patients with greater than five copies of her - 2 / neu had even shorter disease - free survival times (p = 0. 015) and overall survival times (p = 0. 06)'. This demonstrates that higher levels of gene amplification correlate with poorer survival rates.",
    "source": "'patients with greater than five copies of her - 2 / neu had even shorter disease - free survival times (p = 0. 015) and overall survival times (p = 0. 06)'",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:46:05",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.8358161449432373
  },
  {
    "id": 9,
    "repeat_id": 2,
    "question": "What impact does HER-2/neu gene amplification have on patient outcomes according to the excerpt?",
    "answer": "I apologize for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about HER-2/neu gene amplification's impact on patient outcomes without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature or clinical trials that have investigated the relationship between HER-2/neu gene amplification and patient outcomes in cancer patients. These studies typically employ various methodologies such as retrospective analyses of clinical data, randomized controlled trials, or meta-analyses to evaluate the association between HER-2/neu gene amplification (amplification) and survival rates, tumor response, or other relevant endpoints in patients with different types of cancer.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "The excerpt indicates that patients with HER-2/neu gene amplification, particularly those with more than 5 copies, had significantly worse outcomes. Specifically, it states: 'patients with greater than five copies of her - 2 / neu had even shorter disease - free survival times (p = 0. 015) and overall survival times (p = 0. 06)'. This demonstrates that higher levels of gene amplification correlate with poorer survival rates.",
    "source": "'patients with greater than five copies of her - 2 / neu had even shorter disease - free survival times (p = 0. 015) and overall survival times (p = 0. 06)'",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:46:07",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.788583517074585
  },
  {
    "id": 9,
    "repeat_id": 3,
    "question": "What impact does HER-2/neu gene amplification have on patient outcomes according to the excerpt?",
    "answer": "Apologies for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about HER-2/neu gene amplification's impact on patient outcomes without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature or clinical trials that have investigated the relationship between HER-2/neu gene amplification and patient outcomes in cancer patients. These studies typically employ various methodologies such as retrospective analyses of clinical data, randomized controlled trials, or meta-analyses to evaluate the association between HER-2/neu gene amplification (amplification) and survival rates, tumor response, or other relevant endpoints in patients with different types of cancer.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "The excerpt indicates that patients with HER-2/neu gene amplification, particularly those with more than 5 copies, had significantly worse outcomes. Specifically, it states: 'patients with greater than five copies of her - 2 / neu had even shorter disease - free survival times (p = 0. 015) and overall survival times (p = 0. 06)'. This demonstrates that higher levels of gene amplification correlate with poorer survival rates.",
    "source": "'patients with greater than five copies of her - 2 / neu had even shorter disease - free survival times (p = 0. 015) and overall survival times (p = 0. 06)'",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:46:10",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.1506001949310303
  },
  {
    "id": 10,
    "repeat_id": 1,
    "question": "What types of evidence support the link between proto-oncogenes and human malignancies according to the excerpt?",
    "answer": "I apologize for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about evidence supporting the link between proto-oncogenes and human malignancies without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature that investigates the relationship between proto-oncogenes (normal genes involved in cell growth and division) and their corresponding oncogenes (mutated forms leading to uncontrolled cell proliferation). These studies typically employ various methodologies such as genetic analyses, gene expression profiling, or clinical research to assess the association between proto-oncogene alterations and human malignancies.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "The excerpt outlines several types of evidence that support the link between proto-oncogenes and human malignancies. It states that this evidence is derived from 'studies of animal models, tumor cell lines, and actual human tumors.' Additionally, it mentions specific data including 'sequence homology between human proto-oncogenes and the viral oncogenes of transforming retroviruses,' 'transfection studies showing the transforming potential of proto-oncogenes in nih 3 t 3 cells and primary embryo fibroblasts,' and 'the central role of certain proto-oncogenes in tumorigen.' This demonstrates that the relationship is supported by both experimental and comparative studies.",
    "source": "'the evidence linking proto - oncogenes to the induction or maintenance of human malignancies is largely circumstantial, but has become increasingly compelling. this circumstantial evidence is derived from studies of animal models, tumor cell lines, and actual human tumors.'",
    "difficulty": "medium",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:46:12",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.59079647064209
  },
  {
    "id": 10,
    "repeat_id": 2,
    "question": "What types of evidence support the link between proto-oncogenes and human malignancies according to the excerpt?",
    "answer": "Apologies for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about evidence supporting the link between proto-oncogenes and human malignancies without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature that investigates the relationship between proto-oncogenes (normal genes involved in cell growth and division) and their corresponding oncogenes (mutated forms leading to uncontrolled cell proliferation). These studies typically employ various methodologies such as genetic analyses, gene expression profiling, or clinical research to assess the association between proto-oncogene alterations and human malignancies.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "The excerpt outlines several types of evidence that support the link between proto-oncogenes and human malignancies. It states that this evidence is derived from 'studies of animal models, tumor cell lines, and actual human tumors.' Additionally, it mentions specific data including 'sequence homology between human proto-oncogenes and the viral oncogenes of transforming retroviruses,' 'transfection studies showing the transforming potential of proto-oncogenes in nih 3 t 3 cells and primary embryo fibroblasts,' and 'the central role of certain proto-oncogenes in tumorigen.' This demonstrates that the relationship is supported by both experimental and comparative studies.",
    "source": "'the evidence linking proto - oncogenes to the induction or maintenance of human malignancies is largely circumstantial, but has become increasingly compelling. this circumstantial evidence is derived from studies of animal models, tumor cell lines, and actual human tumors.'",
    "difficulty": "medium",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:46:14",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 1.9620397090911865
  },
  {
    "id": 10,
    "repeat_id": 3,
    "question": "What types of evidence support the link between proto-oncogenes and human malignancies according to the excerpt?",
    "answer": "I apologize for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about evidence supporting the link between proto-oncogenes and human malignancies without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature that investigates the relationship between proto-oncogenes (normal genes involved in cell growth and division) and their corresponding oncogenes (mutated forms leading to uncontrolled cell proliferation). These studies typically employ various methodologies such as genetic analyses, gene expression profiling, or clinical research to assess the association between proto-oncogene alterations and human malignancies.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "The excerpt outlines several types of evidence that support the link between proto-oncogenes and human malignancies. It states that this evidence is derived from 'studies of animal models, tumor cell lines, and actual human tumors.' Additionally, it mentions specific data including 'sequence homology between human proto-oncogenes and the viral oncogenes of transforming retroviruses,' 'transfection studies showing the transforming potential of proto-oncogenes in nih 3 t 3 cells and primary embryo fibroblasts,' and 'the central role of certain proto-oncogenes in tumorigen.' This demonstrates that the relationship is supported by both experimental and comparative studies.",
    "source": "'the evidence linking proto - oncogenes to the induction or maintenance of human malignancies is largely circumstantial, but has become increasingly compelling. this circumstantial evidence is derived from studies of animal models, tumor cell lines, and actual human tumors.'",
    "difficulty": "medium",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:46:17",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.6823434829711914
  },
  {
    "id": 11,
    "repeat_id": 1,
    "question": "How does HER-2/neu gene amplification impact prognosis in breast cancer patients, and how does its prognostic value compare to other factors?",
    "answer": "I apologize for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about the impact of HER-2/neu gene amplification on prognosis in breast cancer patients and its comparison with other factors without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature that investigates the relationship between HER-2/neu gene amplification (a specific type of proto-oncogene alteration) and prognosis in breast cancer patients. These studies typically employ various methodologies such as clinical research, genetic analyses, or pathological assessments to evaluate the impact on patient outcomes.\n\nAdditionally, comparing HER-2/neu amplification's prognostic value with other factors involves reviewing literature that assesses its predictive power alongside established prognostic markers (e.g., tumor size, lymph node involvement, hormone receptor status) and other clinical variables.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "According to the excerpt, HER-2/neu gene amplification is a significant predictor of both overall survival and time to relapse in breast cancer patients. The study found that it retained its significance even when adjusted for other known prognostic factors. Notably, HER-2/neu amplification showed greater prognostic value than most currently used factors, including hormonal-receptor status, particularly in lymph node-positive disease. This suggests that the HER-2/neu gene may play a crucial role in the biological behavior and/or pathogenesis of human breast cancer.",
    "source": "amplification of the her - 2 / neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. it retained its significance even when adjustments were made for other known prognostic factors. moreover, her - 2 / neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal - receptor status, in lymph node - positive disease. these data indicate that this gene may play a role in the biologic behavior and / or pathogenesis of human breast cancer.",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:46:20",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.3694140911102295
  },
  {
    "id": 11,
    "repeat_id": 2,
    "question": "How does HER-2/neu gene amplification impact prognosis in breast cancer patients, and how does its prognostic value compare to other factors?",
    "answer": "Apologies for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about the impact of HER-2/neu gene amplification on prognosis in breast cancer patients and its comparison with other factors without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature that investigates the relationship between HER-2/neu gene amplification (a specific type of proto-oncogene alteration) and prognosis in breast cancer patients. These studies typically employ various methodologies such as clinical research, genetic analyses, or pathological assessments to evaluate the impact on patient outcomes.\n\nAdditionally, comparing HER-2/neu amplification's prognostic value with other factors involves reviewing literature that assesses its predictive power alongside established prognostic markers (e.g., tumor size, lymph node involvement, hormone receptor status) and other clinical variables.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "According to the excerpt, HER-2/neu gene amplification is a significant predictor of both overall survival and time to relapse in breast cancer patients. The study found that it retained its significance even when adjusted for other known prognostic factors. Notably, HER-2/neu amplification showed greater prognostic value than most currently used factors, including hormonal-receptor status, particularly in lymph node-positive disease. This suggests that the HER-2/neu gene may play a crucial role in the biological behavior and/or pathogenesis of human breast cancer.",
    "source": "amplification of the her - 2 / neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. it retained its significance even when adjustments were made for other known prognostic factors. moreover, her - 2 / neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal - receptor status, in lymph node - positive disease. these data indicate that this gene may play a role in the biologic behavior and / or pathogenesis of human breast cancer.",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:46:24",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.430708408355713
  },
  {
    "id": 11,
    "repeat_id": 3,
    "question": "How does HER-2/neu gene amplification impact prognosis in breast cancer patients, and how does its prognostic value compare to other factors?",
    "answer": "I apologize for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about the impact of HER-2/neu gene amplification on prognosis in breast cancer patients and its comparison with other factors without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature that investigates the relationship between HER-2/neu gene amplification (a specific type of proto-oncogene alteration) and prognosis in breast cancer patients. These studies typically employ various methodologies such as clinical research, genetic analyses, or pathological assessments to evaluate the impact on patient outcomes.\n\nAdditionally, comparing HER-2/neu amplification's prognostic value with other factors involves reviewing literature that assesses its predictive power alongside established prognostic markers (e.g., tumor size, lymph node involvement, hormone receptor status) and other clinical variables.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "According to the excerpt, HER-2/neu gene amplification is a significant predictor of both overall survival and time to relapse in breast cancer patients. The study found that it retained its significance even when adjusted for other known prognostic factors. Notably, HER-2/neu amplification showed greater prognostic value than most currently used factors, including hormonal-receptor status, particularly in lymph node-positive disease. This suggests that the HER-2/neu gene may play a crucial role in the biological behavior and/or pathogenesis of human breast cancer.",
    "source": "amplification of the her - 2 / neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. it retained its significance even when adjustments were made for other known prognostic factors. moreover, her - 2 / neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal - receptor status, in lymph node - positive disease. these data indicate that this gene may play a role in the biologic behavior and / or pathogenesis of human breast cancer.",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:46:27",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.4403131008148193
  },
  {
    "id": 12,
    "repeat_id": 1,
    "question": "How does HER-2/neu gene amplification relate to patient prognosis in node-positive breast cancer cases?",
    "answer": "I apologize for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about the relationship between HER-2/neu gene amplification and patient prognosis in node-positive breast cancer cases without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature that investigates the association between HER-2/neu gene amplification (a specific type of proto-oncogene alteration) and prognosis in node-positive breast cancer patients. These studies typically employ various methodologies such as clinical research, genetic analyses, or pathological assessments to evaluate the impact on patient outcomes for this subgroup of breast cancer patients with regional lymph node involvement.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "The excerpt indicates that amplification of the HER-2/neu gene is a strong prognostic factor for patients with node-positive breast cancer. Specifically, it states: 'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients.' This demonstrates that HER-2/neu amplification is significant in predicting disease behavior, even when considering other prognostic factors.",
    "source": "'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients, even when other prognostic factors were taken into account'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:46:30",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.9145309925079346
  },
  {
    "id": 12,
    "repeat_id": 2,
    "question": "How does HER-2/neu gene amplification relate to patient prognosis in node-positive breast cancer cases?",
    "answer": "I apologize for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about the relationship between HER-2/neu gene amplification and patient prognosis in node-positive breast cancer cases without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature that investigates the association between HER-2/neu gene amplification (a specific type of proto-oncogene alteration) and prognosis in node-positive breast cancer patients. These studies typically employ various methodologies such as clinical research, genetic analyses, or pathological assessments to evaluate the impact on patient outcomes for this subgroup of breast cancer patients with regional lymph node involvement.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "The excerpt indicates that amplification of the HER-2/neu gene is a strong prognostic factor for patients with node-positive breast cancer. Specifically, it states: 'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients.' This demonstrates that HER-2/neu amplification is significant in predicting disease behavior, even when considering other prognostic factors.",
    "source": "'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients, even when other prognostic factors were taken into account'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:46:33",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.914369583129883
  },
  {
    "id": 12,
    "repeat_id": 3,
    "question": "How does HER-2/neu gene amplification relate to patient prognosis in node-positive breast cancer cases?",
    "answer": "I apologize for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about the relationship between HER-2/neu gene amplification and patient prognosis in node-positive breast cancer cases without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature that investigates the association between HER-2/neu gene amplification (a specific type of proto-oncogene alteration) and prognosis in node-positive breast cancer patients. These studies typically employ various methodologies such as clinical research, genetic analyses, or pathological assessments to evaluate the impact on patient outcomes for this subgroup of breast cancer patients with regional lymph node involvement.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "The excerpt indicates that amplification of the HER-2/neu gene is a strong prognostic factor for patients with node-positive breast cancer. Specifically, it states: 'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients.' This demonstrates that HER-2/neu amplification is significant in predicting disease behavior, even when considering other prognostic factors.",
    "source": "'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients, even when other prognostic factors were taken into account'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:46:36",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.9265336990356445
  },
  {
    "id": 13,
    "repeat_id": 1,
    "question": "What is the statistical significance of HER-2/neu as a prognostic factor for relapse in node-positive breast cancer patients according to the multivariate analysis?",
    "answer": "I apologize for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about the statistical significance of HER-2/neu as a prognostic factor for relapse in node-positive breast cancer patients according to multivariate analysis without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature that investigates the role of HER-2/neu gene amplification (a specific type of proto-oncogene alteration) as a prognostic factor for relapse in node-positive breast cancer patients using multivariate analysis. These studies typically employ statistical methods to assess the independent impact of HER-2/neu on disease recurrence, controlling for other known prognostic factors.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "According to the multivariate analysis presented in the excerpt, HER-2/neu is a statistically significant prognostic factor for relapse in node-positive breast cancer patients. Specifically, the paper states that HER-2/neu has a p-value of '0.001 (0.1378 \u00b1 0.0425)' for relapse in the multivariate analysis. This demonstrates that HER-2/neu is a strong predictor of disease recurrence, with a highly significant p-value of 0.001.",
    "source": "her - 2 / neu 0. 0011 < 0. 0001 0. 02 ( 0. 0872 \u00b1 0. 0388 ) 0. 001 ( 0. 1378 \u00b1 0. 0425 )",
    "difficulty": "hard",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:46:39",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.9286417961120605
  },
  {
    "id": 13,
    "repeat_id": 2,
    "question": "What is the statistical significance of HER-2/neu as a prognostic factor for relapse in node-positive breast cancer patients according to the multivariate analysis?",
    "answer": "I apologize for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about the statistical significance of HER-2/neu as a prognostic factor for relapse in node-positive breast cancer patients according to multivariate analysis without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature that investigates the role of HER-2/neu gene amplification (a specific type of proto-oncogene alteration) as a prognostic factor for relapse in node-positive breast cancer patients using multivariate analysis. These studies typically employ statistical methods to assess the independent impact of HER-2/neu on disease recurrence, controlling for other known prognostic factors.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "According to the multivariate analysis presented in the excerpt, HER-2/neu is a statistically significant prognostic factor for relapse in node-positive breast cancer patients. Specifically, the paper states that HER-2/neu has a p-value of '0.001 (0.1378 \u00b1 0.0425)' for relapse in the multivariate analysis. This demonstrates that HER-2/neu is a strong predictor of disease recurrence, with a highly significant p-value of 0.001.",
    "source": "her - 2 / neu 0. 0011 < 0. 0001 0. 02 ( 0. 0872 \u00b1 0. 0388 ) 0. 001 ( 0. 1378 \u00b1 0. 0425 )",
    "difficulty": "hard",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:46:42",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.915395975112915
  },
  {
    "id": 13,
    "repeat_id": 3,
    "question": "What is the statistical significance of HER-2/neu as a prognostic factor for relapse in node-positive breast cancer patients according to the multivariate analysis?",
    "answer": "I apologize for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about the statistical significance of HER-2/neu as a prognostic factor for relapse in node-positive breast cancer patients according to multivariate analysis without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature that investigates the role of HER-2/neu gene amplification (a specific type of proto-oncogene alteration) as a prognostic factor for relapse in node-positive breast cancer patients using multivariate analysis. These studies typically employ statistical methods to assess the independent impact of HER-2/neu on disease recurrence, controlling for other known prognostic factors.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "According to the multivariate analysis presented in the excerpt, HER-2/neu is a statistically significant prognostic factor for relapse in node-positive breast cancer patients. Specifically, the paper states that HER-2/neu has a p-value of '0.001 (0.1378 \u00b1 0.0425)' for relapse in the multivariate analysis. This demonstrates that HER-2/neu is a strong predictor of disease recurrence, with a highly significant p-value of 0.001.",
    "source": "her - 2 / neu 0. 0011 < 0. 0001 0. 02 ( 0. 0872 \u00b1 0. 0388 ) 0. 001 ( 0. 1378 \u00b1 0. 0425 )",
    "difficulty": "hard",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:46:45",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.9044106006622314
  },
  {
    "id": 14,
    "repeat_id": 1,
    "question": "How does HER-2/neu gene amplification relate to patient prognosis in node-positive breast cancer cases?",
    "answer": "I apologize for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about the relationship between HER-2/neu gene amplification and patient prognosis in node-positive breast cancer cases without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature that investigates the association between HER-2/neu gene amplification (a specific type of proto-oncogene alteration) and prognosis in node-positive breast cancer patients. These studies typically employ various methodologies such as clinical research, genetic analyses, or pathological assessments to evaluate the impact on patient outcomes for this subgroup of breast cancer patients with regional lymph node involvement.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "The excerpt indicates that amplification of the HER-2/neu gene is a strong prognostic factor in node-positive breast cancer patients. Specifically, it states: 'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients.' This demonstrates that HER-2/neu amplification is significant even when considering other prognostic factors.",
    "source": "'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients'",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:46:47",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.8884332180023193
  },
  {
    "id": 14,
    "repeat_id": 2,
    "question": "How does HER-2/neu gene amplification relate to patient prognosis in node-positive breast cancer cases?",
    "answer": "I apologize for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about the relationship between HER-2/neu gene amplification and patient prognosis in node-positive breast cancer cases without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature that investigates the association between HER-2/neu gene amplification (a specific type of proto-oncogene alteration) and prognosis in node-positive breast cancer patients. These studies typically employ various methodologies such as clinical research, genetic analyses, or pathological assessments to evaluate the impact on patient outcomes for this subgroup of breast cancer patients with regional lymph node involvement.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "The excerpt indicates that amplification of the HER-2/neu gene is a strong prognostic factor in node-positive breast cancer patients. Specifically, it states: 'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients.' This demonstrates that HER-2/neu amplification is significant even when considering other prognostic factors.",
    "source": "'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients'",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:46:50",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.879934310913086
  },
  {
    "id": 14,
    "repeat_id": 3,
    "question": "How does HER-2/neu gene amplification relate to patient prognosis in node-positive breast cancer cases?",
    "answer": "I apologize for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts. Therefore, I cannot provide information based on a specific document or study about the relationship between HER-2/neu gene amplification and patient prognosis in node-positive breast cancer cases without additional context.\n\nTo answer your question accurately, you would need to refer to relevant scientific literature that investigates the association between HER-2/neu gene amplification (a specific type of proto-oncogene alteration) and prognosis in node-positive breast cancer patients. These studies typically employ various methodologies such as clinical research, genetic analyses, or pathological assessments to evaluate the impact on patient outcomes for this subgroup of breast cancer patients with regional lymph node involvement.\n\nIf you have access to such a study or excerpt, please provide the details, and I'd be happy to help interpret or summarize the findings based on that information.",
    "ground_truth": "The excerpt indicates that amplification of the HER-2/neu gene is a strong prognostic factor in node-positive breast cancer patients. Specifically, it states: 'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients.' This demonstrates that HER-2/neu amplification is significant even when considering other prognostic factors.",
    "source": "'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients'",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:46:53",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.939135789871216
  },
  {
    "id": 15,
    "repeat_id": 1,
    "question": "Based on the comparison of amplification levels for two related tyrosine kinase receptors in human breast cancer, what conclusion does the excerpt draw regarding the generality of gene amplification as a phenomenon in this specific malignancy?",
    "answer": "I apologize, but I would need the specific excerpt to analyze and provide an accurate response. The question you've posed implies that there's a comparison of gene amplification levels for two related tyrosine kinase receptors in human breast cancer, and we're looking at a conclusion regarding the generality of this phenomenon.\n\nOnce I have access to the relevant excerpt, I can help you draw conclusions based on the information presented there.",
    "ground_truth": "The excerpt concludes that the significant difference in amplification levels between the two related tyrosine kinase receptors suggests that gene amplification is not a universally applicable phenomenon for this class of receptors in human breast cancer. Specifically, the paper states: \"of the former to be 14 times greater than that of the latter, indicating that the phenomenon of gene amplification is not a general one for a related tyrosine kinase - specific receptor in human breast cancer.\"",
    "source": "of the former to be 14 times greater than that of the latter, indicating that the phenomenon of gene amplification is not a general one for a related tyrosine kinase - specific receptor in human breast cancer.",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:46:55",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 1.8351576328277588
  },
  {
    "id": 15,
    "repeat_id": 2,
    "question": "Based on the comparison of amplification levels for two related tyrosine kinase receptors in human breast cancer, what conclusion does the excerpt draw regarding the generality of gene amplification as a phenomenon in this specific malignancy?",
    "answer": "I apologize for any confusion earlier. As I don't have access to external text or excerpts, I can't directly analyze or provide information based on a specific document you're referring to. However, I can give you a general idea of how such an analysis might proceed:\n\nThe excerpt likely discusses a study comparing the amplification levels of two related tyrosine kinase receptors in human breast cancer samples. The conclusion drawn would depend on the findings from this comparison. \n\n1. If the study found consistent and significant gene amplification across various breast cancer subtypes or stages, it might suggest that gene amplification is a common phenomenon in human breast cancer, potentially serving as an important prognostic or therapeutic target.\n\n2. Conversely, if the study revealed limited or inconsistent amplification across different breast cancer types, it could imply that gene amplification might not be a universal feature in this malignancy, and its significance may vary depending on specific contexts (e.g., tumor subtype, stage).\n\n3. The excerpt would also likely discuss the clinical or biological relevance of these findings, such as their implications for diagnosis, prognosis, or treatment strategies in breast cancer.\n\nTo provide a precise conclusion based on your specific excerpt, I would need to see the text itself.",
    "ground_truth": "The excerpt concludes that the significant difference in amplification levels between the two related tyrosine kinase receptors suggests that gene amplification is not a universally applicable phenomenon for this class of receptors in human breast cancer. Specifically, the paper states: \"of the former to be 14 times greater than that of the latter, indicating that the phenomenon of gene amplification is not a general one for a related tyrosine kinase - specific receptor in human breast cancer.\"",
    "source": "of the former to be 14 times greater than that of the latter, indicating that the phenomenon of gene amplification is not a general one for a related tyrosine kinase - specific receptor in human breast cancer.",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:46:59",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.728830099105835
  },
  {
    "id": 15,
    "repeat_id": 3,
    "question": "Based on the comparison of amplification levels for two related tyrosine kinase receptors in human breast cancer, what conclusion does the excerpt draw regarding the generality of gene amplification as a phenomenon in this specific malignancy?",
    "answer": "I apologize for any confusion earlier. As I don't have access to external text or excerpts, I can't directly analyze or provide information based on a specific document you're referring to. However, I can give you a general idea of how such an analysis might proceed:\n\nThe excerpt likely discusses a study comparing the amplification levels of two related tyrosine kinase receptors in human breast cancer samples. The conclusion drawn would depend on the findings from this comparison. \n\n\n1. If the study found consistent and significant gene amplification across various breast cancer subtypes or stages, it might suggest that gene amplification is a common phenomenon in human breast cancer, potentially serving as an important prognostic or therapeutic target.\n\n2. Conversely, if the study revealed limited or inconsistent amplification across different breast cancer types, it could imply that gene amplification might not be a universal feature in this malignancy, and its significance may vary depending on specific contexts (e.g., tumor subtype, stage).\n\n3. The excerpt would also likely discuss the clinical or biological relevance of these findings, such as their implications for diagnosis, prognosis, or treatment strategies in breast cancer.\n\nTo provide a precise conclusion based on your specific excerpt, I would need to see the text itself.",
    "ground_truth": "The excerpt concludes that the significant difference in amplification levels between the two related tyrosine kinase receptors suggests that gene amplification is not a universally applicable phenomenon for this class of receptors in human breast cancer. Specifically, the paper states: \"of the former to be 14 times greater than that of the latter, indicating that the phenomenon of gene amplification is not a general one for a related tyrosine kinase - specific receptor in human breast cancer.\"",
    "source": "of the former to be 14 times greater than that of the latter, indicating that the phenomenon of gene amplification is not a general one for a related tyrosine kinase - specific receptor in human breast cancer.",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:47:03",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.7319705486297607
  },
  {
    "id": 16,
    "repeat_id": 1,
    "question": "What statistical method was used to evaluate the predictive power of prognostic factors in the study?",
    "answer": "I apologize for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts, including specific studies or their methodologies. Therefore, I cannot provide information on the statistical methods used in a particular study without having that document available.\n\nTo accurately answer your question, you would need to refer to the actual research paper or study where the evaluation of prognostic factors and the employed statistical methods are detailed. Commonly used statistical methods for evaluating predictive power include:\n\n1. Univariate Analysis: This initial step involves examining each prognostic factor individually using tests like Chi-square, Fisher's exact test, or Kruskal-Wallis test (for categorical variables) and t-tests or ANOVA (for continuous variables).\n\n2. Multivariable Analysis: Techniques such as Cox Proportional Hazards Regression are often used to assess the independent effect of multiple prognostic factors on survival, controlling for potential confounders.\n\n3. Receiver Operating Characteristic (ROC) Curves and Area Under the Curve (AUC): These methods are employed to evaluate the predictive accuracy of binary classification models.\n\n4. Logistic Regression: Used when the outcome is binary (e.g., survival vs. death), it can assess the impact of various factors on the probability of an event occurring.\n\n5. Survival Analysis: Methods like Kaplan-Meier curves and Cox Proportional Hazards Model are specifically designed to analyze time-to-event data, such as overall survival or progression-free survival.\n\nTo determine which specific method was used in a given study, you would need to consult the original research paper or its supplementary materials.",
    "ground_truth": "The study utilized Cox's partial nonparametric regression model to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner. Specifically, the paper states: 'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.' This demonstrates that the researchers aimed to analyze multiple factors simultaneously to understand their impact on patient outcomes.",
    "source": "'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.'",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:47:07",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.393366575241089
  },
  {
    "id": 16,
    "repeat_id": 2,
    "question": "What statistical method was used to evaluate the predictive power of prognostic factors in the study?",
    "answer": "I apologize for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts, including specific studies or their methodologies. Therefore, I cannot provide information on the statistical methods used in a particular study without having that document available.\n\nTo accurately answer your question, you would need to refer to the actual research paper or study where the evaluation of prognostic factors and the employed statistical methods are detailed. Commonly used statistical methods for evaluating predictive power include:\n\n1. Univariate Analysis: This initial step involves examining each prognostic factor individually using tests like Chi-square, Fisher's exact test, or Kruskal-Wallis test (for categorical variables) and t-tests or ANOVA (for continuous variables).\n\n2. Multivariable Analysis: Techniques such as Cox Proportional Hazards Regression are often used to assess the independent effect of multiple prognostic factors on survival, controlling for potential confounders.\n\n3. Receiver Operating Characteristic (ROC) Curves and Area Under the Curve (AUC): These methods are employed to evaluate the predictive accuracy of binary classification models.\n\n4. Logistic Regression: Used when the outcome is binary (e.g., survival vs. death), it can assess the impact of various factors on the probability of an event occurring.\n\n5. Survival Analysis: Methods like Kaplan-Meier curves and Cox Proportional Hazards Model are specifically designed to analyze time-to-event data, such as overall survival or progression-free survival.\n\nTo determine which specific method was used in a given study, you would need to consult the original research paper or its supplementary materials.",
    "ground_truth": "The study utilized Cox's partial nonparametric regression model to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner. Specifically, the paper states: 'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.' This demonstrates that the researchers aimed to analyze multiple factors simultaneously to understand their impact on patient outcomes.",
    "source": "'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.'",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:47:11",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.3680994510650635
  },
  {
    "id": 16,
    "repeat_id": 3,
    "question": "What statistical method was used to evaluate the predictive power of prognostic factors in the study?",
    "answer": "I apologize for any confusion earlier, but as previously mentioned, I don't have access to external text or excerpts, including specific studies or their methodologies. Therefore, I cannot provide information on the statistical methods used in a particular study without having that document available.\n\nTo accurately answer your question, you would need to refer to the actual research paper or study where the evaluation of prognostic factors and the employed statistical methods are detailed. Commonly used statistical methods for evaluating predictive power include:\n\n1. Univariate Analysis: This initial step involves examining each prognostic factor individually using tests like Chi-square, Fisher's exact test, or Kruskal-Wallis test (for categorical variables) and t-tests or ANOVA (for continuous variables).\n\n2. Multivariable Analysis: Techniques such as Cox Proportional Hazards Regression are often used to assess the independent effect of multiple prognostic factors on survival, controlling for potential confounders.\n\n3. Receiver Operating Characteristic (ROC) Curves and Area Under the Curve (AUC): These methods are employed to evaluate the predictive accuracy of binary classification models.\n\n4. Logistic Regression: Used when the outcome is binary (e.g., survival vs. death), it can assess the impact of various factors on the probability of an event occurring.\n\n5. Survival Analysis: Methods like Kaplan-Meier curves and Cox Proportional Hazards Model are specifically designed to analyze time-to-event data, such as overall survival or progression-free survival.\n\nTo determine which specific method was used in a given study, you would need to consult the original research paper or its supplementary materials.",
    "ground_truth": "The study utilized Cox's partial nonparametric regression model to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner. Specifically, the paper states: 'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.' This demonstrates that the researchers aimed to analyze multiple factors simultaneously to understand their impact on patient outcomes.",
    "source": "'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.'",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:47:16",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.300206422805786
  },
  {
    "id": 17,
    "repeat_id": 1,
    "question": "Based on the structural description provided in the excerpt for the protein identified as \"[Chunk 8]\", what specific features lead to the inference that it is likely a cellular receptor?",
    "answer": "I apologize, but I don't have access to external text or excerpts, including the specific structural descriptions you're referring to. To answer your question accurately, I would need to see the detailed description of \"[Chunk 8]\" as provided in the excerpt. \n\nHowever, based on general knowledge, here are some features that often indicate a protein's role as a cellular receptor:\n\n1. **Ligand-Binding Site**: A prominent feature is the presence of a specific cleft or pocket where small molecules (ligands) can bind. These ligands typically include hormones, growth factors, neurotransmitters, etc., and their binding to the receptor triggers cellular responses.\n\n2. **Transmembrane Domains**: Proteins acting as receptors often have multiple transmembrane helices that span the plasma membrane, creating an extracellular ligand-binding domain and an intracellular signaling domain.\n\n3. **Intracellular Signaling Motifs**: Upon ligand binding, these proteins initiate intracellular signaling cascades by interacting with intracellular signaling molecules like kinases or G proteins.\n\n4. **Conformational Changes**: Binding of a ligand to the receptor often induces conformational changes that activate the protein and allow it to interact with downstream signaling partners.\n\n5. **Homology to Known Receptors**: Sequence analysis might reveal homology to known receptors, suggesting a similar function.\n\nWithout the specific structural description for \"[Chunk 8]\", I can't provide a definitive answer as to which features would lead to its classification as a cellular receptor.",
    "ground_truth": "According to the excerpt, the inference that the protein \"[Chunk 8]\" is likely a cellular receptor is based on its specific domain structure. The text states: \"[Chunk 8] has an extracellular domain, a transmembrane domain that includes two cysteine - rich repeat clusters, and an intracellular kinase domain, indicating that it too is likely to be a cellular receptor for an as yet unidentified ligand.\" These distinct domains, particularly the extracellular and transmembrane components, are characteristic of receptor proteins.",
    "source": "[Chunk 8] has an extracellular domain, a transmembrane domain that includes two cysteine - rich repeat clusters, and an intracellular kinase domain, indicating that it too is likely to be a cellular receptor for an as yet unidentified ligand.",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:47:20",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.216329097747803
  },
  {
    "id": 17,
    "repeat_id": 2,
    "question": "Based on the structural description provided in the excerpt for the protein identified as \"[Chunk 8]\", what specific features lead to the inference that it is likely a cellular receptor?",
    "answer": "I apologize, but I don't have access to external text or excerpts, including the specific structural descriptions you're referring to. To answer your question accurately, I would need to see the detailed description of \"[Chunk 8]\" as provided in the excerpt. \n\nHowever, based on general knowledge, here are some features that often indicate a protein's role as a cellular receptor:\n\n1. **Ligand-Binding Site**: A prominent feature is the presence of a specific cleft or pocket where small molecules (ligands) can bind. These ligands typically include hormones, growth factors, neurotransmitters, etc., and their binding to the receptor triggers cellular responses.\n\n2. **Transmembrane Domains**: Proteins acting as receptors often have multiple transmembrane helices that span the plasma membrane, creating an extracellular ligand-binding domain and an intracellular signaling domain.\n\n3. **Intracellular Signaling Motifs**: Upon ligand binding, these proteins initiate intracellular signaling cascades by interacting with intracellular signaling molecules like kinases or G proteins.\n\n4. **Conformational Changes**: Binding of a ligand to the receptor often induces conformational changes that activate the protein and allow it to interact with downstream signaling partners.\n\n5. **Homology to Known Receptors**: Sequence analysis might reveal homology to known receptors, suggesting a similar function.\n\nWithout the specific structural description for \"[Chunk 8]\", I can't provide a definitive answer as to which features would lead to its classification as a cellular receptor.",
    "ground_truth": "According to the excerpt, the inference that the protein \"[Chunk 8]\" is likely a cellular receptor is based on its specific domain structure. The text states: \"[Chunk 8] has an extracellular domain, a transmembrane domain that includes two cysteine - rich repeat clusters, and an intracellular kinase domain, indicating that it too is likely to be a cellular receptor for an as yet unidentified ligand.\" These distinct domains, particularly the extracellular and transmembrane components, are characteristic of receptor proteins.",
    "source": "[Chunk 8] has an extracellular domain, a transmembrane domain that includes two cysteine - rich repeat clusters, and an intracellular kinase domain, indicating that it too is likely to be a cellular receptor for an as yet unidentified ligand.",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:47:24",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.184071779251099
  },
  {
    "id": 17,
    "repeat_id": 3,
    "question": "Based on the structural description provided in the excerpt for the protein identified as \"[Chunk 8]\", what specific features lead to the inference that it is likely a cellular receptor?",
    "answer": "Apologies for any confusion, but I'm unable to access external text or excerpts, including the specific structural descriptions you're referring to. To accurately answer your question, I would need to see the detailed description of \"[Chunk 8]\" as provided in the excerpt. \n\nHowever, based on general knowledge, here are some features that often indicate a protein's role as a cellular receptor:\n\n1. **Ligand-Binding Site**: A prominent feature is the presence of a specific cleft or pocket where small molecules (ligands) can bind. These ligands typically include hormones, growth factors, neurotransmitters, etc., and their binding to the receptor triggers cellular responses.\n\n2. **Transmembrane Domains**: Proteins acting as receptors often have multiple transmembrane helices that span the plasma membrane, creating an extracellular ligand-binding domain and an intracellular signaling domain.\n\n3. **Intracellular Signaling Motifs**: Upon ligand binding, these proteins initiate intracellular signaling cascades by interacting with intracellular signaling molecules like kinases or G proteins.\n\n4. **Conformational Changes**: Binding of a ligand to the receptor often induces conformational changes that activate the protein and allow it to interact with downstream signaling partners.\n\n5. **Homology to Known Receptors**: Sequence analysis might reveal homology to known receptors, suggesting a similar function.\n\nWithout the specific structural description for \"[Chunk 8]\", I can't provide a definitive answer as to which features would lead to its classification as a cellular receptor.",
    "ground_truth": "According to the excerpt, the inference that the protein \"[Chunk 8]\" is likely a cellular receptor is based on its specific domain structure. The text states: \"[Chunk 8] has an extracellular domain, a transmembrane domain that includes two cysteine - rich repeat clusters, and an intracellular kinase domain, indicating that it too is likely to be a cellular receptor for an as yet unidentified ligand.\" These distinct domains, particularly the extracellular and transmembrane components, are characteristic of receptor proteins.",
    "source": "[Chunk 8] has an extracellular domain, a transmembrane domain that includes two cysteine - rich repeat clusters, and an intracellular kinase domain, indicating that it too is likely to be a cellular receptor for an as yet unidentified ligand.",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:47:28",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.217039108276367
  },
  {
    "id": 18,
    "repeat_id": 1,
    "question": "What statistical method was used to evaluate the predictive power of prognostic factors in the study?",
    "answer": "I apologize, but as previously mentioned, I don't have access to external text or excerpts, including specific studies or their methodologies. Therefore, I can't provide information on the statistical methods used in a particular study without having that document available. \n\nTo accurately answer your question, you would need to refer to the actual research paper or study where the evaluation of prognostic factors and the employed statistical methods are detailed. Commonly used statistical methods for evaluating predictive power include:\n\n1. Univariate Analysis: This initial step involves examining each prognostic factor individually using tests like Chi-square, Fisher's exact test, or Kruskal-Wallis test (for categorical variables) and t-tests or ANOVA (for continuous variables).\n\n2. Multivariable Analysis: Techniques such as Cox Proportional Hazards Regression are often used to assess the independent effect of multiple prognostic factors on survival, controlling for potential confounders.\n\n3. Receiver Operating Characteristic (ROC) Curves and Area Under the Curve (AUC): These methods are employed to evaluate the performance of predictive models.\n\n4. Logistic Regression: Useful when the outcome is binary (e.g., survival or death).\n\n5. Survival Analysis: Particularly Kaplan-Meier curves and Cox Proportional Hazards Models, which are used to analyze time-to-event data.\n\n6. Machine Learning Algorithms: Such as Random Forests, Support Vector Machines, or Neural Networks, for more complex predictive modeling tasks.\n\nWithout the specific study details, I can't pinpoint the exact method used in this case.",
    "ground_truth": "The study utilized Cox's partial nonparametric regression model to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner. Specifically, the paper states: 'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.' This demonstrates that the researchers aimed to analyze multiple factors simultaneously to understand their impact on patient outcomes.",
    "source": "'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.'",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:47:32",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.215471029281616
  },
  {
    "id": 18,
    "repeat_id": 2,
    "question": "What statistical method was used to evaluate the predictive power of prognostic factors in the study?",
    "answer": "I apologize for any confusion, but as previously mentioned, I don't have access to external text or excerpts, including specific studies or their methodologies. Therefore, I can't provide information on the statistical methods used in a particular study without having that document available. \n\nTo accurately answer your question, you would need to refer to the actual research paper or study where the evaluation of prognostic factors and the employed statistical methods are detailed. Commonly used statistical methods for evaluating predictive power include:\n\n1. Univariate Analysis: This initial step involves examining each prognostic factor individually using tests like Chi-square, Fisher's exact test, or Kruskal-Wallis test (for categorical variables) and t-tests or ANOVA (for continuous variables).\n\n2. Multivariable Analysis: Techniques such as Cox Proportional Hazards Regression are often used to assess the independent effect of multiple prognostic factors on survival, controlling for potential confounders.\n\n3. Receiver Operating Characteristic (ROC) Curves and Area Under the Curve (AUC): These methods are employed to evaluate the performance of predictive models.\n\n4. Logistic Regression: Useful when the outcome is binary (e.g., survival or death).\n\n5. Survival Analysis: Particularly Kaplan-Meier curves and Cox Proportional Hazards Models, which are used to analyze time-to-event data.\n\n6. Machine Learning Algorithms: Such as Random Forests, Support Vector Machines, or Neural Networks, for more complex predictive modeling tasks.\n\nWithout the specific study details, I can't pinpoint the exact method used in this case.",
    "ground_truth": "The study utilized Cox's partial nonparametric regression model to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner. Specifically, the paper states: 'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.' This demonstrates that the researchers aimed to analyze multiple factors simultaneously to understand their impact on patient outcomes.",
    "source": "'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.'",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:47:37",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.1993248462677
  },
  {
    "id": 18,
    "repeat_id": 3,
    "question": "What statistical method was used to evaluate the predictive power of prognostic factors in the study?",
    "answer": "I apologize for any confusion, but as previously mentioned, I don't have access to external text or excerpts, including specific studies or their methodologies. Therefore, I can't provide information on the statistical methods used in a particular study without having that document available. \n\nTo accurately answer your question, you would need to refer to the actual research paper or study where the evaluation of prognostic factors and the employed statistical methods are detailed. Commonly used statistical methods for evaluating predictive power include:\n\n1. Univariate Analysis: This initial step involves examining each prognostic factor individually using tests like Chi-square, Fisher's exact test, or Kruskal-Wallis test (for categorical variables) and t-tests or ANOVA (for continuous variables).\n\n2. Multivariable Analysis: Techniques such as Cox Proportional Hazards Regression are often used to assess the independent effect of multiple prognostic factors on survival, controlling for potential confounders.\n\n3. Receiver Operating Characteristic (ROC) Curves and Area Under the Curve (AUC): These methods are employed to evaluate the performance of predictive models.\n\n4. Logistic Regression: Useful when the outcome is binary (e.g., survival or death).\n\n5. Survival Analysis: Particularly Kaplan-Meier curves and Cox Proportional Hazards Models, which are used to analyze time-to-event data.\n\n6. Machine Learning Algorithms: Such as Random Forests, Support Vector Machines, or Neural Networks, for more complex predictive modeling tasks.\n\nWithout the specific study details, I can't pinpoint the exact method used in this case.",
    "ground_truth": "The study utilized Cox's partial nonparametric regression model to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner. Specifically, the paper states: 'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.' This demonstrates that the researchers aimed to analyze multiple factors simultaneously to understand their impact on patient outcomes.",
    "source": "'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.'",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:47:41",
    "model_name": "granite3.3:2b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.179705858230591
  }
]